A semi-mechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans
Journal of Bone and Mineral Research, 03/12/2013Cabal A et al.
JTT–305/MK–5442 is a Calcium Sensing Receptor (CaSR) allosteric antagonist being investigated for the treatment of osteoporosis. The model describes both the dose–dependence of PTH Tmax and Cmax, and the extent and duration of the observed non–monotonic return of PTH to baseline levels following JTT–305/MK–5442 administration.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.